What is the current Price Target for the Compass Therapeutics stock?

The average Compass Therapeutics target price is $10.71. This is 175.32% higher than the current stock price. The highest price target is 763.75%, the lowest is 81.75%. 12 Analysts have issued a price target Compass Therapeutics 2026 .

How high will the Compass Therapeutics stock rise?

No reliable answer can be given as to how high the Compass Therapeutics stock will rise. The performance of stocks, including the Compass Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Compass Therapeutics stock today?

The performance of Compass Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Compass Therapeutics stock fall?

The decline in Compass Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Compass Therapeutics Forecast, price target & analysts

$3.97

2.06% today

NYSE, Oct 24, 10:00 pm CET

ISIN

US20454B1044

Symbol

CMPX

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Compass Therapeutics Target price 2025 - Analyst rating & recommendation

Compass Therapeutics Classifications & Recommendation:

Buy

94%

Hold

Compass Therapeutics Price Target

Target Price	$10.71
Price	$3.89
Potential	175.32% register free of charge
Number of Estimates	12

	12 Analysts have issued a price target Compass Therapeutics 2026 . The average Compass Therapeutics target price is $10.71. This is 175.32% register free of charge higher than the current stock price. The highest price target is $33.60 763.75% register free of charge , the lowest is $7.07 81.75% register free of charge .
	A rating was issued by 16 analysts: 15 Analysts recommend Compass Therapeutics to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Compass Therapeutics stock has an average upside potential 2026 of 175.32% register free of charge . Most analysts recommend the Compass Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-0.36	-0.56
	9.09%	55.56%
P/E		negative

12 Analysts have issued a Compass Therapeutics forecast for earnings per share. The average Compass Therapeutics EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-0.36	9.09%
2025	$-0.56 55.56% Unlock
2026	$-0.58 3.57% Unlock
2027	$-0.56 3.45% Unlock
2028	$-0.02 96.43% Unlock
2029	$0.57 2,950.00% Unlock
2030	$1.93 238.60% Unlock
2031	$4.67 141.97% Unlock
2032	$6.78 45.18% Unlock

Current	-11.79	128.15%
2025	-6.91 41.38% Unlock
2026	-6.73 2.60% Unlock
2027	-6.92 2.82% Unlock
2028	-228.37 3,200.14% Unlock
2029	6.79 102.97% Unlock
2030	2.01 70.40% Unlock
2031	0.83 58.71% Unlock
2032	0.57 31.33% Unlock

Compass Therapeutics...

Current Compass Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
LifeSci Capital	Locked ➜ Locked	Locked	Oct 06 2025
Guggenheim	Locked ➜ Locked	Locked	Aug 12 2025
D. Boral Capital	Locked ➜ Locked	Locked	Aug 12 2025
Raymond James	Locked ➜ Locked	Locked	Jul 01 2025
Guggenheim	Locked ➜ Locked	Locked	May 09 2025
D. Boral Capital	Locked ➜ Locked	Locked	Apr 28 2025
Guggenheim	Locked ➜ Locked	Locked	Apr 22 2025

Analyst Rating	Date
Locked LifeSci Capital: Locked ➜ Locked	Oct 06 2025
Locked Guggenheim: Locked ➜ Locked	Aug 12 2025
Locked D. Boral Capital: Locked ➜ Locked	Aug 12 2025
Locked Raymond James: Locked ➜ Locked	Jul 01 2025
Locked Guggenheim: Locked ➜ Locked	May 09 2025
Locked D. Boral Capital: Locked ➜ Locked	Apr 28 2025
Locked Guggenheim: Locked ➜ Locked	Apr 22 2025

Discover more stocks with a high price target

TUI 50.73%

Deutsche Telekom 33.66%

BioNTech SE - ADR 33.40%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now